Search results
Showing 16 to 30 of 152 results for copd
Endobronchial nerve ablation for chronic obstructive pulmonary disease (HTG604)
Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.
View recommendations for HTG604Show all sections
In development Reference number: GID-TA11246 Expected publication date: 05 March 2026
All NICE products on chronic obstructive pulmonary disease. Includes any guidance, advice and quality standards.
In development Reference number: GID-HTE10065 Expected publication date: 02 April 2026
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Smoking: smoking status of people with long-term conditions (IND156)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126
Recommendation ID NG115/3 Question Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of...
Lung volume reduction surgery for advanced emphysema (HTG69)
Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.
View recommendations for HTG69Show all sections
Sections for HTG69
NG115/6 Question Diagnosing COPD: - What are the characteristics of people diagnosed with COPD as a result of an...
This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
antibiotics for preventing exacerbations:- Which subgroups of people with stable COPD who are at high risk of exacerbations are most...